MedBulletinsAura Celeste
Endocrinology

Monthly endocrinology and diabetes bulletin — November 10, 2026

🎧 Listen to this issueAudio newscast · 6:22 min

This issue covers what was published, presented or approved between October 11 and November 10, 2026. The month was shaped by the American Heart Association Scientific Sessions (Chicago, November 6-9), with several cardiometabolic studies relevant to endocrinology, the EMA's positive opinion for oral orforglipron, and a new FDA warning on optic neuropathy for all GLP-1 receptor agonists. Ten items; four from outside North America and Western Europe (Russia, Brazil, Japan and Israel). There are no bone items this month.

Type 1 and type 2 diabetes

1. Continuous glucose monitoring in non-insulin-treated type 2 diabetes: −0.9 points of HbA1c vs usual care (CONNECT)

[Clinical trial] [United States]
Published in NEJM on October 14 (Oser et al.; senior author Roy W. Beck, JAEB Center): a 26-week randomized trial in 22 US primary care practices in adults with type 2 diabetes not using insulin. According to MedTech Dive, 145 participants were assigned to the Dexcom G7 and 138 to usual care. HbA1c fell from 8.8% to 7.2% with CGM vs 8.7% to 8.0% with usual care; according to the Dexcom press release, the difference was 0.9 points, with about five more hours per day in the 70-180 mg/dL range, and 46% of the CGM group reached HbA1c below 7%.
Why it matters: it supports CGM in type 2 diabetes without insulin in primary care, but it was funded by Dexcom and lasted only six months. Local applicability will depend on cost, coverage, and support for sensor use. Whether the effect lasts without study support remains to be seen.

Sources

2. Russia registers teplizumab to delay clinical type 1 diabetes

[Regulatory Minzdrav] [Russia / France]
According to GxP News (October 22) and Pharmvestnik (October 23), the Russian Ministry of Health entered teplizumab (Tezild, Sanofi), given as an intravenous infusion, in the state medicines register to delay progression from stage 2 to stage 3 type 1 diabetes; according to Pharmvestnik, in adults and children aged 8 and older. According to GxP News, the basis is the 76-patient trial in which median time to clinical diagnosis was 50 months with teplizumab vs 25 months with placebo, and progression to stage 3 occurred in 45% vs 72%.
Why it matters: it extends access outside the US to a therapy that delays the clinical diagnosis of type 1 diabetes. Implementation requires identifying stage 2 type 1 diabetes and access to specialist assessment and follow-up; the pivotal evidence is still one small trial. (source in Russian)

Sources

3. GLP-1 vs metformin in prediabetes with obesity: more reversion to normoglycemia in a records-based study

[Meeting] [United States]
Presented at AHA 2026 (abstract MDP1524): a matched cohort of electronic health records from the TriNetX network. According to the American Heart Association release, records from 256,492 adults with prediabetes and obesity across 104 institutions were analyzed, with an average follow-up of about three years; about half were taking GLP-1 receptor agonists and the other half metformin. According to Healio and HCPLive, reversion to normoglycemia was 37.3% with GLP-1 receptor agonists vs 29.3% with metformin (HR 1.53; 95% CI 1.51-1.55) and progression to type 2 diabetes 25.1% vs 37% (HR 0.69; 95% CI 0.68-0.70); all-cause mortality had an HR of 0.59 (95% CI 0.55-0.63).
Why it matters: it is observational, based on diagnosis codes and prescription records, and unpublished; the association with 41% lower mortality may be affected by residual confounding and does not establish a causal effect (the author urged cautious interpretation). It does not change practice: metformin remains the inexpensive option with randomized evidence for prevention.

Sources

Obesity and metabolism

4. Survodutide meets the cardiovascular noninferiority criterion in obesity (SYNCHRONIZE-CVOT)

[Clinical trial] [International / Germany]
Presented at AHA 2026 on November 9 with simultaneous publication in The Lancet: a phase 3, randomized, double-blind, placebo-controlled, event-driven trial (NCT06077864). According to the Boehringer Ingelheim press release, it enrolled 5,530 adults with obesity or overweight and established cardiovascular or chronic kidney disease, or at least two complications or risk factors, assigned to weekly survodutide 3.6 mg, 6.0 mg or placebo. 5-point MACE: HR 0.89 (95% CI 0.67-1.18), non-inferiority met; 3-point MACE: HR 0.84 (95% CI 0.60-1.18). With the supplementary estimand, weight loss reached 13.7% vs 2.0% at 72 weeks and systolic blood pressure fell by up to 6.7 vs 1.8 mm Hg. Discontinuation for gastrointestinal events: 19.3% and 20.8% vs 1.9%.
Why it matters: it is a safety trial and does not show cardiovascular benefit; the 13.7% figure comes from a supplementary estimand, and about one in five participants stopped because of GI intolerance. Sponsored by Boehringer Ingelheim.

Sources

5. EMA recommends approval of oral orforglipron for obesity and type 2 diabetes

[Regulatory EMA] [European Union / United States]
At its October 12-15 meeting (highlights published October 16), the CHMP recommended authorizing Foundayo (orforglipron, Lilly), an oral GLP-1 receptor agonist taken as a once-daily tablet, for the treatment of obesity and type 2 diabetes in adults; at the same meeting it recommended an extension of indication for Kyinsu (insulin icodec/semaglutide). According to the Saudi regulator (SFDA) statement as reported by Dawaa News, in the 72-week trials with the 36 mg dose weight loss was 11.2% vs 2.1% with placebo in obesity without diabetes (n=3,127) and 9.6% vs 2.5% in obesity with type 2 diabetes (n=1,613).
Why it matters: the trials are placebo-controlled, with no head-to-head comparison against injectable GLP-1 drugs; a daily pill may ease access, but the final decision rests with the European Commission, and price will determine its role in our region.

Sources

6. Orforglipron reduces obstructive sleep apnea severity (ATTAIN-OSA)

[Clinical trial] [International / United States]
Presented at AHA 2026 and published in JAMA on November 9: two phase 3, randomized, double-blind, placebo-controlled, 52-week trials in adults with moderate to severe sleep apnea and obesity or overweight, at 66 sites in nine countries (712 randomized). Without PAP (n=363; baseline AHI 50.7), the apnea-hypopnea index changed by −17.8 events per hour vs −4.5 with placebo; with PAP (n=349; baseline AHI 57.6), by −17.3 vs −5.3 (treatment-regimen estimand). According to Healio, weight fell 10% to 11% vs 1% to 2%, and systolic blood pressure 7 to 8 mm Hg vs 1 to 3 mm Hg.
Why it matters: with mean baseline AHIs of 50.7 and 57.6, a mean reduction of about 17 to 18 events per hour leaves a still-elevated residual AHI; it is an adjunct, not a substitute for PAP. Several authors are affiliated with Eli Lilly; no active comparator.

Sources

7. Brazil approves five new liraglutide and semaglutide pens made in India

[Regulatory ANVISA] [Brazil / India]
On October 29, Anvisa approved five products: Aribet (liraglutide, diabetes), Lyrza and Wylovol (liraglutide, obesity), registered by Farma Vision and manufactured by Biocon; and Embeltah (semaglutide, diabetes, Dr. Reddy's) and Sevema (semaglutide, diabetes, Aché), both manufactured by OneSource Specialty. According to Anvisa, this brings the number of pens approved in 2026 to 20, under the prioritization started in August 2025 at the request of the Ministry of Health to supply the public health system.
Why it matters: it widens the supply of non-originator liraglutide and semaglutide in the region; the effect on prices and access remains to be seen, and post-marketing surveillance of these products should be followed. The official notice does not say whether they are synthetic or biotechnological. (source in Portuguese)

Sources

Thyroid, adrenal and pituitary

8. Japan: loss of paternally inherited DIO3 linked to infantile-onset central hypothyroidism (case report)

[Publication] [Japan]
Published online in Thyroid on October 24 (Gifu University and Hiroshima University; press release November 5): the case of an infant whose newborn TSH and free T4 screening was within thresholds, but with neonatal T-cell lymphopenia detected by TREC screening. From 5 months of age, free T4 declined without a compensatory TSH rise. Chromosomal microarray showed a 14q32.31-q32.33 deletion including DIO3 and TRAF3, derived from a paternal balanced 4p/14q translocation. According to the press release, it is the first human description of this mechanism.
Why it matters: it is a single case and does not change general practice, but it is a reminder that a normal TSH-based newborn screen does not rule out later-onset central hypothyroidism. (source in Japanese)

Sources

Bone and reproductive endocrinology

9. Menopausal hormone therapy started at age 45-59: no association with higher cardiovascular or thrombosis risk was observed over 12 years

[Meeting] [Israel]
Presented at AHA 2026 (abstract MDP0654). According to the American Heart Association release, an observational matched cohort in Clalit Health Services records of 52,330 women aged 45 to 59, followed for a mean of 12 years, with similar results across all formulations and routes (oral, patch or gel). According to Healio (November 6), the cohort was retrospective, with a target-trial design, of women free of atherosclerotic cardiovascular disease, venous thromboembolism and cancer at baseline, half of them initiating hormone therapy; venous thromboembolism: adjusted HR 1.01 (95% CI 0.82-1.24); atherosclerotic cardiovascular disease: 0.98 (0.93-1.04); death before age 80: 1.03 (0.92-1.15); composite: 1.00 (0.96-1.06).
Why it matters: no association with higher cardiovascular risk was observed when therapy was started near menopause, but it is observational, with possible unmeasured confounding, not peer reviewed, and classifies route by first prescription; the lack of excess thrombosis with oral therapy contrasts with the trials and calls for caution.

Sources

Cross-cutting

10. FDA requires a warning on nonarteritic anterior ischemic optic neuropathy (NAION) for all GLP-1 receptor agonists

[Regulatory FDA] [United States]
On November 9, the FDA required holders of all GLP-1 receptor agonist applications to add the potential risk of nonarteritic anterior ischemic optic neuropathy to the Warnings and Precautions section of labeling. In a meta-analysis of 126 trials there were 10 cases among 78,217 treated patients vs 5 among 56,036 controls (6.4 vs 3.8 per 100,000 person-years); in a Sentinel cohort of type 2 diabetes (2019-2024), risk was higher than with DPP-4 inhibitors and not significantly different from SGLT2 inhibitors. It advises telling patients to report sudden, painless vision loss in one eye immediately, referring to ophthalmology, and considering discontinuation.
Why it matters: the absolute risk is very low and the signal is inconsistent across comparators, but the class warning is now official and should be part of informed consent and patient education.

Sources

Upcoming meetings and dates

World Diabetes Day, November 14. ObesityWeek 2026, Washington, D.C., November 14-17: according to Novo Nordisk, primary results of REDEFINE 9 (low-dose CagriSema; poster on November 15) will be presented.
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=919290

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.